Cell Host Microbe. 2010 Sep 16;8(3):271-83. doi: 10.1016/j.chom.2010.08.007.

The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.

Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F.

Source

Institute for Research in Biomedicine, Bellinzona 6500, Switzerland.

Abstract

Antibodies protect against homologous Dengue virus (DENV) infection but can precipitate severe dengue by promoting heterotypic virus entry via Fcγ receptors (FcγR). We immortalized memory B cells from individuals after primary or secondary infection and analyzed anti-DENV monoclonal antibodies (mAbs) thus generated. MAbs to envelope (E) protein domain III (DIII) were either serotype specific or cross-reactive and potently neutralized DENV infection. DI/DII- or viral membrane protein prM-reactive mAbs neutralized poorly and showed broad cross-reactivity with the four DENV serotypes. All mAbs enhanced infection at subneutralizing concentrations. Three mAbs targeting distinct epitopes on the four DENV serotypes and engineered to prevent FcγR binding did not enhance infection and neutralized DENV in vitro and in vivo as postexposure therapy in a mouse model of lethal DENV infection. Our findings reveal an unexpected degree of cross-reactivity in human antibodies against DENV and illustrate the potential for an antibody-based therapy to control severe dengue.

PMID:: 20833378; [PubMed - indexed for MEDLINE]

Publication Types, MeSH Terms, Substances, Grant Support

Publication Types

MeSH Terms

Substances

Grant Support

LinkOut - more resources

Full Text Sources

Medical

Dengue - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Review The human antibody response to dengue virus infection. [Viruses. 2011]
Review The human antibody response to dengue virus infection.
Wahala WM, Silva AM. Viruses. 2011 Dec; 3(12):2374-95. Epub 2011 Nov 25.
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. [J Virol. 2007]
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes.
Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken GE, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, et al. J Virol. 2007 Dec; 81(23):12816-26. Epub 2007 Sep 19.
Genotype-specific neutralization and protection by antibodies against dengue virus type 3. [J Virol. 2010]
Genotype-specific neutralization and protection by antibodies against dengue virus type 3.
Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS. J Virol. 2010 Oct; 84(20):10630-43. Epub 2010 Aug 11.
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. [Proc Natl Acad Sci U S A. 2012]
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions.
de Alwis R, Smith SA, Olivarez NP, Messer WB, Huynh JP, Wahala WM, White LJ, Diamond MS, Baric RS, Crowe JE Jr, et al. Proc Natl Acad Sci U S A. 2012 May 8; 109(19):7439-44. Epub 2012 Apr 12.
Review Immune response to dengue virus and prospects for a vaccine. [Annu Rev Immunol. 2011]
Review Immune response to dengue virus and prospects for a vaccine.
Murphy BR, Whitehead SS. Annu Rev Immunol. 2011; 29:587-619.

See reviews... See all...

Cited by 31 PubMed Central articles

The importance of hematopoietic progenitor cells in dengue. [Ther Adv Hematol. 2012]
The importance of hematopoietic progenitor cells in dengue.
Tsai JJ, Liu LT, Chang K, Wang SH, Hsiao HM, Clark KB, Perng GC. Ther Adv Hematol. 2012 Feb; 3(1):59-71.
Therapeutic efficacy of antibodies lacking FcγR against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies. [PLoS Pathog. 2013]
Therapeutic efficacy of antibodies lacking FcγR against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies.
Williams KL, Sukupolvi-Petty S, Beltramello M, Johnson S, Sallusto F, Lanzavecchia A, Diamond MS, Harris E. PLoS Pathog. 2013 Feb; 9(2):e1003157. Epub 2013 Feb 14.
Rational engineering of a human anti-dengue antibody through experimentally validated computational docking. [PLoS One. 2013]
Rational engineering of a human anti-dengue antibody through experimentally validated computational docking.
Simonelli L, Pedotti M, Beltramello M, Livoti E, Calzolai L, Sallusto F, Lanzavecchia A, Varani L. PLoS One. 2013; 8(2):e55561. Epub 2013 Feb 6.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
MedGen
Related information in MedGen
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

The human immune response to Dengue virus is dominated by highly cross-reactive ...
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity.
Cell Host Microbe. 2010 Sep 16 ;8(3):271-83. doi: 10.1016/j.chom.2010.08.007.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: